

Alison Martin¹, Alexandra Furber¹¹ Crystallise Ltd**Objectives:**

Health Technology Assessments may require modellers to identify existing economic evaluations for a range of jurisdictions quickly and in an unbiased way. We aimed to create an Evidence Map of cost-effectiveness model publications in rheumatoid arthritis (RA) to facilitate this process.

Methods:

- We searched the heoro.com database (www.heoro.com) for cost-effectiveness, cost-utility and cost-benefit models in RA published between 1960 and 24th October 2018.
- Abstracts identified by the search were indexed to determine the publication date, jurisdiction, stage of disease, interventions assessed, type of economic evaluation and modelling perspective.
- We presented the results as an Evidence Map.

Results:



We identified 94 independent publications.

Table 1: Type of model by jurisdiction.

	Cost-effectiveness	Cost-utility	Protocol	Review
Australia	0	0	0	1
Austria	1	0	0	0
Bulgaria	0	1	0	0
Canada	1	0	0	1
Czech Republic	0	1	0	0
Finland	0	1	0	0
France	2	2	0	0
Germany	4	4	0	0
Greece	0	2	0	0
Hungary	0	1	0	0
International	0	0	0	5
Italy	1	4	0	0
Netherlands	4	18	2	1
Poland	0	1	0	0
Romania	0	1	0	0
Serbia	1	0	0	0
Slovakia	0	1	0	0
Spain	3	0	0	0
Sweden	0	2	0	0
Switzerland	0	1	0	0
UK	4	30	2	3
Unclear	0	1	0	0

Table 3: Subpopulation assessed by model perspective.

	Healthcare	Societal	Unclear
Biological-naïve	16	8	5
Early	9	8	1
Remission	1	0	0
Second-line biological	11	1	3
Third-line biological	3	0	1
Unclear	18	9	11

**Figure 1:** the Heoro.com dashboard**Figure 2:** Number of publications by jurisdiction**Figure 3:** Number of publications by year of publication**Table 2:** Interventions modelled

Intervention	Number of models
Abatacept	9
Adalimumab	22
Anakinra	1
Biologicals	4
CBT	1
Certolizumab	5
Ciclosporin	1
Corticosteroids	2
DMARDs	7
Diagnosis	3
Education	2
Etanercept	22
Exercise	4
Golimumab	3
Infliximab	18
Leflunomide	4
Methotrexate	24
NSAIDs	2
Rituximab	15
Screening	1
Service design	7
TNF- α inhibitors	5
Test for TB	1
Tocilizumab	5
Treat-to-target	6
Unclear	5
Workplace adaptation	2
Abatacept	9

Conclusions:

- Economic evaluations in RA that were published in PubMed have mainly been developed for biological therapies in European jurisdictions, in particular the UK.
- This reflects the importance of health technology assessments to assess new interventions in these countries.
- For a chronic, disabling condition that often affects working-age adults, the relatively small number of models that had a societal perspective is surprising.